These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 31957468)
1. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468 [TBL] [Abstract][Full Text] [Related]
2. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Myhre PL; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Beldhuis IE; Fleg JL; Lewis E; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS Circ Heart Fail; 2018 Nov; 11(11):e005312. PubMed ID: 30571192 [TBL] [Abstract][Full Text] [Related]
3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411 [TBL] [Abstract][Full Text] [Related]
4. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305 [TBL] [Abstract][Full Text] [Related]
5. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936 [TBL] [Abstract][Full Text] [Related]
6. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD; JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923 [TBL] [Abstract][Full Text] [Related]
7. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA; Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133 [TBL] [Abstract][Full Text] [Related]
8. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406 [TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068 [TBL] [Abstract][Full Text] [Related]
10. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. Merrill M; Sweitzer NK; Lindenfeld J; Kao DP JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379 [TBL] [Abstract][Full Text] [Related]
11. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E; JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142 [TBL] [Abstract][Full Text] [Related]
15. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557 [TBL] [Abstract][Full Text] [Related]
16. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186 [TBL] [Abstract][Full Text] [Related]
17. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739 [TBL] [Abstract][Full Text] [Related]
18. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190 [TBL] [Abstract][Full Text] [Related]
19. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]